Novo Nordisk board discussed supply issues at every meeting in 2022
How to meet surging demand for some of the Danish drugmaker’s most popular drugs was amongst the most debated topics at the year’s board meetings, Chair Helge Lund says.
by marketwire, translated by daniel pedersen
Over the course of last year, the board of directors at Novo Nordisk has been very focused on expanding production facilities to meet the demand of some highly sought-after products, informed Chairman Helge Lund at the Danish drugmaker’s annual general meeting on Thursday.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
All Wegovy dose strengths are back on US market
For subscribers
